Director/PDMR Shareholding

By

Regulatory News | 04 Feb, 2020

Updated : 12:01

RNS Number : 9192B
Tiziana Life Sciences PLC
04 February 2020
 

Tiziana Life Science plc

PDMR Dealing

New York/London, 4 February 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 3 February 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 5,000 ADSs (each representing 5 Ordinary Shares) at a price of $2.37 per ADS, as set out below.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

1.

Details of PDMR / person closely associated

a)

Name

Gabriele Cerrone/Panetta Partners Limited

2.

Reason for the notification: On market acquisition

a)

Position / status

Executive Chairman

b)

Initial notification /amendment

Initial notification

3.

Details of the issuer

a)

Name

Tiziana Life Sciences plc

b)

LEI

213800CED47HI8PIOB36

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

ADS representing 5 Ordinary Shares

b)

Identification code of the Financial Instrument

US88875G1013

c)

Nature of the transaction

On market acquisition of ordinary shares

d)

Price(s) and volume(s)

Price: $2.37 

Volume: 5,000

 

e)

Aggregated information

- Aggregated volume

- Price

 

5,000

$11,850

f)

Date of the transaction

3 February 2020

g)

Place of the transaction

NASDAQ

As a result of this transaction Mr Cerrone's interests in the underlying ordinary shares of the Company increases from 64,346,925 (47.087%) to 64,351,925 (47.156%). Mr Cerrone's interests in the ordinary shares of the Company are based on a holding of 63,680,404 ordinary shares held by Planwise Limited and voting rights in respect of 671,521 ordinary shares held by Panetta Partners Limited (as shares and via ADSs). Mr Cerrone is considered beneficially interested in the holdings of Panetta Partners Limited and Planwise Limited.

For more information go to http://www.tizianalifesciences.com

Contacts:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

+44 (0)20 7213 0883

Shore Capital (Broker)

Antonio Bossi / Fiona Conroy

+44 (0)20 7408 4050

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBBGDDUSGDGGS

Last news